BACKGROUND:Tiotropium has activity as an asthma controller. However, predictors of a positive response to tiotropium have not been described. OBJECTIVE: We sought to describe individual and differential responses of asthmatic patients tosalmeterol and tiotropium when added to an inhaled corticosteroid, as well as predictors of a positive clinical response. METHODS: Data from the double-blind, 3-way, crossover National Heart, Lung, and Blood Institute's Asthma Clinical Research Network's Tiotropium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (ClinicalTrials.gov number, NCT00565266) trial were analyzed for individual and differential treatment responses to salmeterol and tiotropium and predictors of a positive response to the end points FEV1, morning peak expiratory flow (PEF), and asthma control days (ACDs). RESULTS: Although approximately equal numbers of patients showed a differential response to salmeterol and tiotropium in terms of morning PEF (n = 90 and 78, respectively) and ACDs (n = 49 and 53, respectively), more showed a differential response to tiotropium for FEV1 (n = 104) than salmeterol (n = 62). An acute response to a short-acting bronchodilator, especially albuterol, predicted a positive clinical response to tiotropium for FEV1 (odds ratio, 4.08; 95% CI, 2.00-8.31; P < .001) and morning PEF (odds ratio, 2.12; 95% CI, 1.12-4.01; P = 0.021), as did a decreased FEV1/forced vital capacity ratio (FEV1 response increased 0.39% of baseline for every 1% decrease in FEV1/forced vital capacity ratio). Higher cholinergic tone was also a predictor, whereas ethnicity, sex, atopy, IgE level, sputum eosinophil count, fraction of exhaled nitric oxide, asthma duration, and body mass index were not. CONCLUSION: Although these results require confirmation, predictors of a positive clinical response to tiotropium include a positive response to albuterol and airway obstruction, factors that could help identify appropriate patients for this therapy.
RCT Entities:
BACKGROUND:Tiotropium has activity as an asthma controller. However, predictors of a positive response to tiotropium have not been described. OBJECTIVE: We sought to describe individual and differential responses of asthmatic patients to salmeterol and tiotropium when added to an inhaled corticosteroid, as well as predictors of a positive clinical response. METHODS: Data from the double-blind, 3-way, crossover National Heart, Lung, and Blood Institute's Asthma Clinical Research Network's Tiotropium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (ClinicalTrials.gov number, NCT00565266) trial were analyzed for individual and differential treatment responses to salmeterol and tiotropium and predictors of a positive response to the end points FEV1, morning peak expiratory flow (PEF), and asthma control days (ACDs). RESULTS: Although approximately equal numbers of patients showed a differential response to salmeterol and tiotropium in terms of morning PEF (n = 90 and 78, respectively) and ACDs (n = 49 and 53, respectively), more showed a differential response to tiotropium for FEV1 (n = 104) than salmeterol (n = 62). An acute response to a short-acting bronchodilator, especially albuterol, predicted a positive clinical response to tiotropium for FEV1 (odds ratio, 4.08; 95% CI, 2.00-8.31; P < .001) and morning PEF (odds ratio, 2.12; 95% CI, 1.12-4.01; P = 0.021), as did a decreased FEV1/forced vital capacity ratio (FEV1 response increased 0.39% of baseline for every 1% decrease in FEV1/forced vital capacity ratio). Higher cholinergic tone was also a predictor, whereas ethnicity, sex, atopy, IgE level, sputum eosinophil count, fraction of exhaled nitric oxide, asthma duration, and body mass index were not. CONCLUSION: Although these results require confirmation, predictors of a positive clinical response to tiotropium include a positive response to albuterol and airway obstruction, factors that could help identify appropriate patients for this therapy.
Authors: Huib A M Kerstjens; Bernd Disse; Winfried Schröder-Babo; Theo A Bantje; Martina Gahlemann; Ralf Sigmund; Michael Engel; Jan A van Noord Journal: J Allergy Clin Immunol Date: 2011-06-02 Impact factor: 10.793
Authors: Richard J Martin; Stanley J Szefler; Tonya S King; Monica Kraft; Homer A Boushey; Vernon M Chinchilli; Timothy J Craig; Emily A Dimango; Aaron Deykin; John V Fahy; Elliot Israel; Stephen C Lazarus; Robert F Lemanske; Frank T Leone; Gene R Pesola; Stephen P Peters; Christine A Sorkness; Lisa A Szwejbka; Michael E Wechsler Journal: J Allergy Clin Immunol Date: 2007-01 Impact factor: 10.793
Authors: Stephen P Peters; Susan J Kunselman; Nikolina Icitovic; Wendy C Moore; Rodolfo Pascual; Bill T Ameredes; Homer A Boushey; William J Calhoun; Mario Castro; Reuben M Cherniack; Timothy Craig; Loren Denlinger; Linda L Engle; Emily A DiMango; John V Fahy; Elliot Israel; Nizar Jarjour; Shamsah D Kazani; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Njira Lugogo; Richard J Martin; Deborah A Meyers; Joe Ramsdell; Christine A Sorkness; E Rand Sutherland; Stanley J Szefler; Stephen I Wasserman; Michael J Walter; Michael E Wechsler; Vernon M Chinchilli; Eugene R Bleecker Journal: N Engl J Med Date: 2010-09-19 Impact factor: 91.245
Authors: Ruth H Green; Christopher E Brightling; Susan McKenna; Beverley Hargadon; Debbie Parker; Peter Bradding; Andrew J Wardlaw; Ian D Pavord Journal: Lancet Date: 2002-11-30 Impact factor: 79.321
Authors: Huib A M Kerstjens; Michael Engel; Ronald Dahl; Pierluigi Paggiaro; Ekkehard Beck; Mark Vandewalker; Ralf Sigmund; Wolfgang Seibold; Petra Moroni-Zentgraf; Eric D Bateman Journal: N Engl J Med Date: 2012-09-02 Impact factor: 91.245
Authors: Robert S Zeiger; Stanley J Szefler; Brenda R Phillips; Michael Schatz; Fernando D Martinez; Vernon M Chinchilli; Robert F Lemanske; Robert C Strunk; Gary Larsen; Joseph D Spahn; Leonard B Bacharier; Gordon R Bloomberg; Theresa W Guilbert; Gregory Heldt; Wayne J Morgan; Mark H Moss; Christine A Sorkness; Lynn M Taussig Journal: J Allergy Clin Immunol Date: 2006-01 Impact factor: 10.793
Authors: Stanley J Szefler; Brenda R Phillips; Fernando D Martinez; Vernon M Chinchilli; Robert F Lemanske; Robert C Strunk; Robert S Zeiger; Gary Larsen; Joseph D Spahn; Leonard B Bacharier; Gordon R Bloomberg; Theresa W Guilbert; Gregory Heldt; Wayne J Morgan; Mark H Moss; Christine A Sorkness; Lynn M Taussig Journal: J Allergy Clin Immunol Date: 2005-02 Impact factor: 10.793
Authors: Sunita Sharma; Augusto A Litonjua; Kelan G Tantisira; Anne L Fuhlbrigge; Stanley J Szefler; Robert C Strunk; Robert S Zeiger; Amy J Murphy; Scott T Weiss Journal: J Allergy Clin Immunol Date: 2008-10-10 Impact factor: 10.793
Authors: Jason E Knuffman; Christine A Sorkness; Robert F Lemanske; David T Mauger; Susan J Boehmer; Fernando D Martinez; Leonard B Bacharier; Robert C Strunk; Stanley J Szefler; Robert S Zeiger; Lynn M Taussig Journal: J Allergy Clin Immunol Date: 2009-01-03 Impact factor: 10.793
Authors: Alan P Baptist; Wei Hao; Keerthi R Karamched; Bani Kaur; Laurie Carpenter; Peter X K Song Journal: J Allergy Clin Immunol Pract Date: 2017-07-27
Authors: Matthew G Drake; Gregory D Scott; Emily D Blum; Katherine M Lebold; Zhenying Nie; James J Lee; Allison D Fryer; Richard W Costello; David B Jacoby Journal: Sci Transl Med Date: 2018-09-05 Impact factor: 17.956